Nurix Therapeutics (NRIX) Operating Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has reported Operating Leases for 6 consecutive years, with $54.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Leases rose 846.93% year-over-year to $54.9 million; the TTM figure through May 2026 stood at $54.9 million (up 846.93% YoY), while the FY2025 annual figure was $52.9 million, up 160.76% from the prior year.
• Operating Leases declined to $54.9 million in Q2 2026 per NRIX's latest filing, from $55.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $55.5 million in Q1 2026 and bottomed at $2.6 million in Q3 2023.
• Historically, Operating Leases has averaged $21.9 million across 5 years, with a median of $20.1 million in 2024.
• Annual changes were most pronounced in 2025 — Operating Leases plunged 72.23% — and 2026, when it soared 846.93%.
• Nurix Therapeutics' Operating Leases stood at $6.4 million in 2022, then surged by 259.42% to $23.1 million in 2023, then dropped by 12.26% to $20.3 million in 2024, then surged by 160.76% to $52.9 million in 2025, then climbed by 3.81% to $54.9 million in 2026.
• Business Quant data shows NRIX's Operating Leases at $54.9 million in Q2 2026, $55.5 million in Q1 2026, and $52.9 million in Q4 2025.